Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD20xCD3 Bispecific Antibody + GemOx/Polatuzumab Vedotin Before CAR T-Cell Therapy in R/R Aggressive B-Cell NHL
NCT07883135Phase 2Recruiting
- Sponsor
- National Medical Research Center for Hematology
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, epcoritamab in non-Hodgkin lymphoma (NHL), sponsored by National Medical Research Center for Hematology. Started Sep 2026; status: recruiting.
02
Drugs
glofitamabepcoritamab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07883135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883135.